Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms

J. Stetka, M. Usart, L. Kubovcakova, S. Rai, TN. Rao, J. Sutter, H. Hao-Shen, S. Dirnhofer, F. Geier, MS. Bader, JR. Passweg, V. Manolova, F. Dürrenberger, N. Ahmed, T. Schroeder, T. Ganz, E. Nemeth, L. Silvestri, A. Nai, C. Camaschella, RC. Skoda

. 2023 ; 141 (17) : 2127-2140. [pub] 2023Apr27

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23011701

JAK 2-V617F mutation causes myeloproliferative neoplasms (MPNs) that can manifest as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis. At diagnosis, patients with PV already exhibited iron deficiency, whereas patients with ET had normal iron stores. We examined the influence of iron availability on MPN phenotype in mice expressing JAK2-V617F and in mice expressing JAK2 with an N542-E543del mutation in exon 12 (E12). At baseline, on a control diet, all JAK2-mutant mouse models with a PV-like phenotype displayed iron deficiency, although E12 mice maintained more iron for augmented erythropoiesis than JAK2-V617F mutant mice. In contrast, JAK2-V617F mutant mice with an ET-like phenotype had normal iron stores comparable with that of wild-type (WT) mice. On a low-iron diet, JAK2-mutant mice and WT controls increased platelet production at the expense of erythrocytes. Mice with a PV phenotype responded to parenteral iron injections by decreasing platelet counts and further increasing hemoglobin and hematocrit, whereas no changes were observed in WT controls. Alterations of iron availability primarily affected the premegakaryocyte-erythrocyte progenitors, which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant mice. The orally administered ferroportin inhibitor vamifeport and the minihepcidin PR73 normalized hematocrit and hemoglobin levels in JAK2-V617F and E12 mutant mouse models of PV, suggesting that ferroportin inhibitors and minihepcidins could be used in the treatment for patients with PV.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011701
003      
CZ-PrNML
005      
20230801133252.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2022017976 $2 doi
035    __
$a (PubMed)36758212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stetka, Jan $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000343012856
245    10
$a Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms / $c J. Stetka, M. Usart, L. Kubovcakova, S. Rai, TN. Rao, J. Sutter, H. Hao-Shen, S. Dirnhofer, F. Geier, MS. Bader, JR. Passweg, V. Manolova, F. Dürrenberger, N. Ahmed, T. Schroeder, T. Ganz, E. Nemeth, L. Silvestri, A. Nai, C. Camaschella, RC. Skoda
520    9_
$a JAK 2-V617F mutation causes myeloproliferative neoplasms (MPNs) that can manifest as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis. At diagnosis, patients with PV already exhibited iron deficiency, whereas patients with ET had normal iron stores. We examined the influence of iron availability on MPN phenotype in mice expressing JAK2-V617F and in mice expressing JAK2 with an N542-E543del mutation in exon 12 (E12). At baseline, on a control diet, all JAK2-mutant mouse models with a PV-like phenotype displayed iron deficiency, although E12 mice maintained more iron for augmented erythropoiesis than JAK2-V617F mutant mice. In contrast, JAK2-V617F mutant mice with an ET-like phenotype had normal iron stores comparable with that of wild-type (WT) mice. On a low-iron diet, JAK2-mutant mice and WT controls increased platelet production at the expense of erythrocytes. Mice with a PV phenotype responded to parenteral iron injections by decreasing platelet counts and further increasing hemoglobin and hematocrit, whereas no changes were observed in WT controls. Alterations of iron availability primarily affected the premegakaryocyte-erythrocyte progenitors, which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant mice. The orally administered ferroportin inhibitor vamifeport and the minihepcidin PR73 normalized hematocrit and hemoglobin levels in JAK2-V617F and E12 mutant mouse models of PV, suggesting that ferroportin inhibitors and minihepcidins could be used in the treatment for patients with PV.
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    _2
$a železo $7 D007501
650    12
$a myeloproliferativní poruchy $x farmakoterapie $x genetika $x diagnóza $7 D009196
650    12
$a polycythaemia vera $x genetika $7 D011087
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    12
$a esenciální trombocytemie $x genetika $7 D013920
650    _2
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a hemoglobiny $x genetika $7 D006454
650    12
$a deficit železa $7 D000090463
655    _2
$a časopisecké články $7 D016428
700    1_
$a Usart, Marc $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Kubovcakova, Lucia $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Rai, Shivam $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Rao, Tata Nageswara $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0000000299285944
700    1_
$a Sutter, Joshua $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0000000245568973
700    1_
$a Hao-Shen, Hui $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
700    1_
$a Dirnhofer, Stefan $u Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
700    1_
$a Geier, Florian $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland $u Swiss Institute of Bioinformatics, Basel, Switzerland
700    1_
$a Bader, Michael S $u Division of Hematology, University Hospital Basel, Basel, Switzerland
700    1_
$a Passweg, Jakob R $u Division of Hematology, University Hospital Basel, Basel, Switzerland
700    1_
$a Manolova, Vania $u CSL Vifor, St. Gallen, Switzerland $1 https://orcid.org/0000000220728942
700    1_
$a Dürrenberger, Franz $u CSL Vifor, St. Gallen, Switzerland
700    1_
$a Ahmed, Nouraiz $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
700    1_
$a Schroeder, Timm $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland $1 https://orcid.org/0000000193200252
700    1_
$a Ganz, Tomas $u David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA $1 https://orcid.org/0000000228305469 $7 xx0301621
700    1_
$a Nemeth, Elizabeta $u David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA $1 https://orcid.org/0000000234772397
700    1_
$a Silvestri, Laura $u Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy $u Vita Salute San Raffaele University, Milan, Italy
700    1_
$a Nai, Antonella $u Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy $u Vita Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000207395282
700    1_
$a Camaschella, Clara $u Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy $1 https://orcid.org/0000000314270143
700    1_
$a Skoda, Radek C $u Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0000000236269496
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 141, č. 17 (2023), s. 2127-2140
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36758212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133248 $b ABA008
999    __
$a ok $b bmc $g 1963883 $s 1197966
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 141 $c 17 $d 2127-2140 $e 2023Apr27 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options